Rana McKay, MD

Rana McKay, MD, is a medical oncologist at the University of California, San Diego Moores Cancer Center.

Articles by Rana McKay, MD

Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their excitement for the road ahead in kidney cancer.
View More
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
Michael Morris, MDRoundtable | November 16, 2023
The panel shares insights on future advancements in the field.
Michael Morris, MDRoundtable | November 16, 2023
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
Michael Morris, MDRoundtable | November 16, 2023
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.